Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab

Journal of Virology

Volumn 85, Issue 8, 2011, Pages 3872-3880

  Toma, Jonathan ^a   Weinheimer, Steven P ^b   Stawiski, Eric ^a   Whitcomb, Jeannette M ^a   Lewis, Stanley T ^b   Petropoulos, Christos J ^a   Huang, Wei ^a  

^a MONOGRAM BIOSCIENCES   (United States)

^b TaiMed Biologics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; CD4 ANTIBODY; ENFUVIRTIDE; IBALIZUMAB; MARAVIROC; RPA T 4; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; SITE DIRECTED MUTAGENESIS; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS MUTATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ASPARAGINE; CLINICAL TRIALS AS TOPIC; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; MYOVIRIDAE; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79952832247     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02237-10     Document Type: Article

References (46)

1. Anastassopoulou, C. G., T. J. Ketas, P. J. Klasse, and J. P. Moore. 2009. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 106:5318-5323.
2. Ashish, et al. 2008. Conformational rearrangement within the soluble domains of the CD4 receptor is ligand-specific. J. Biol. Chem. 283:2761-2772.
3. Ashkenazi, A., et al. 1991. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. Proc. Natl. Acad. Sci. U. S. A. 88:7056-7060.
4. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
5. Burkly, L. C., et al. 1992. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J. Immunol. 149:1779-1787.
6. Derdeyn, C. A., et al. 2001. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75:8605-8614. (Pubitemid 32768965)
7. Doms, R. W., and J. P. Moore. 2000. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 151:F9-F14.
8. Etemad, B., et al. 2009. Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J. Virol. 83:9694-9708.
9. Fatkenheuer, G., et al. 2008. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N. Engl. J. Med. 359:1442-1455.
10. Haim, H., et al. 2009. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 5:e1000360.
11. Jacobson, J. M., et al. 2009. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents Chemother. 53:450-457.
12. Kitrinos, K. M., H. Amrine-Madsen, D. M. Irlbeck, J. M. Word, and J. F. Demarest. 2009. Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope. Antimicrob. Agents Chemother. 53:1124-1131.
13. Klasse, P. J., and Q. J. Sattentau. 1996. Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4. AIDS Res. Hum. Retroviruses 12:1015-1021.
14. Koch, M., et al. 2003. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313:387-400. (Pubitemid 37045357)
15. Kuritzkes, D. R., et al. 2004. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189:286-291.
16. Kwong, P. D., et al. 1998. Structure of an HIV gp 120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659. (Pubitemid 28289647)
17. Mascola, J. R., and D. C. Montefiori. 2003. HIV-1: nature's master of disguise. Nat. Med. 9:393-394.
18. McNicholas, P., et al. Characterization of emergent HIV resistance in treatment- naive subjects enrolled in a vicriviroc phase 2 trial. J. Infect. Dis. 201:1470-1480.
19. Melby, T., et al. 2006. Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res. Hum. Retroviruses 22:375-385.
20. Moore, J. P., Q. J. Sattentau, P. J. Klasse, and L. C. Burkly. 1992. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. J. Virol. 66:4784-4793.
21. Norris, D., et al. 2006. TNX-355, in combination with optimized background regiment (OBR), achieves statistically significant viral load reduction and CD4 cell count increases when compared with OBR alone in phase 2 study at 48 weeks, abstr. THLB0128. XVI Int. AIDS Conf., 13-18 August 2006, Toronto, Canada.
22. Orloff, S. L., M. S. Kennedy, A. A. Belperron, P. J. Maddon, and J. S. McDougal. 1993. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J. Virol. 67:1461-1471.
23. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2009. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC.
24. Peters, P. J., et al. 2008. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope:CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology 5:5.
25. Pinter, A., et al. 2004. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 78:5205-5215. (Pubitemid 38581472)
26. Pugach, P., et al. 2007. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361:212-228. (Pubitemid 46551222)
27. Reimann, K. A., et al. 1993. In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AIDS Res. Hum. Retroviruses 9:199-207.
28. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986-993.
29. Sarkar, G., and S. S. Sommer. 1990. The "megaprimer" method of site-directed mutagenesis. Biotechniques 8:404-407.
30. Sattentau, Q. J., and J. P. Moore. 1993. The role of CD4 in HIV binding and entry. Philos. Trans. R. Soc. Lond. B Biol. Sci. 342:59-66.
31. Sista, P. R., et al. 2004. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18:1787-1794. (Pubitemid 39179630)
32. Song, R., et al. Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J. Virol. 84:6935-6942.
33. Sterjovski, J., et al. 2007. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 4:89.
34. Thomas, E. R., et al. 2007. Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology 360:105-119.
35. Tilton, J. C., et al. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res. Hum. Retroviruses 26:13-24.
36. Trkola, A., et al. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187. (Pubitemid 26386476)
37. Tsibris, A. M., et al. 2008. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 82:8210-8214.
38. Utachee, P., et al. 2010. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01-AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. J. Virol. 84:4311-4320.
39. Wei, X., et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
40. Wei, X., et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. (Pubitemid 36378357)
41. Westby, M., et al. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909-4920.
42. Westby, M., et al. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371.
43. Whitcomb, J. M., et al. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575.
44. Wu, L., et al. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179-183. (Pubitemid 26386475)
45. Wyatt, R., et al. 1998. The antigenic structure of the HIV gp 120 envelope glycoprotein. Nature 393:705-710.
46. Zhang, X. Q., M. Sorensen, M. Fung, and R. T. Schooley. 2006. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob. Agents Chemother. 50:2231-2233.